Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1002/cmdc.202200088
Title (Primary) Front cover: Andrographolide derivatives target the KEAP1/NRF2 axis and possess potent anti-SARS-CoV-2 activity (ChemMedChem 5/2022)
Author Schulte, B.; König, M.; Escher, B.I. ORCID logo ; Wittenburg, S.; Proj, M.; Wolf, V.; Lemke, C.; Schnakenburg, G.; Sosič, I.; Streeck, H.; Müller, C.E.; Gütschow, M.; Steinebach, C.
Source Titel ChemMedChem
Year 2022
Department ZELLTOX
Volume 17
Issue 5
Page From e202200088
Language englisch
Topic T9 Healthy Planet
Keywords SARS-CoV-2; andrographolide; KEAP1/NRF2; natural products; medicinal chemistry
Abstract The Front Cover illustrates the natural product andrographolide, which modulates the abundance of the transcription factor NRF2, a substrate of the E3 ligase KEAP1. Previous studies identified that this drug possessed anti-SARS-CoV-2 activity, but the mechanism of action remained unclear. The authors designed and synthesized novel andrographolide derivatives with a functional site to fine-tune physicochemical properties and for linker attachment. The team assayed this new set of compounds in a cell-based NRF2 reporter gene assay and determined their ability to decrease infectivity of virus-treated Vero-E6 cells. Data showed that NRF2 activation by compounds and inhibition of SARS-CoV-2 replication correlated well. The study opens new avenues to investigate natural products that target the KEAP1/NRF2 axis as anti-SARS-CoV-2 agents. More information can be found in the Research Article by Christian Steinebach et al.
Schulte, B., König, M., Escher, B.I., Wittenburg, S., Proj, M., Wolf, V., Lemke, C., Schnakenburg, G., Sosič, I., Streeck, H., Müller, C.E., Gütschow, M., Steinebach, C. (2022):
Front cover: Andrographolide derivatives target the KEAP1/NRF2 axis and possess potent anti-SARS-CoV-2 activity (ChemMedChem 5/2022)
ChemMedChem 17 (5), e202200088 10.1002/cmdc.202200088